Plasmid-Mediated Cephalosporinase ACC-1 in Clinical Isolates of Proteus mirabilis and Escherichia coli

2000 ◽  
Vol 19 (11) ◽  
pp. 893-895 ◽  
Author(s):  
D. Girlich ◽  
A. Karim ◽  
C. Spicq ◽  
P. Nordmann
Keyword(s):  
Escherichia Coli ◽  
Proteus Mirabilis ◽  
Clinical Isolates

scholarly journals Conjugative plasmidic AmpC detected in Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae human clinical isolates from Portugal

2020 ◽  
Vol 51 (4) ◽  
pp. 1807-1812
Author(s):  
Gabrielli Stefaninni Santiago ◽  
Daniela Gonçalves ◽  
Irene da Silva Coelho ◽  
Shana de Mattos de Oliveira Coelho ◽  
Helena Neto Ferreira
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Proteus Mirabilis ◽  
Clinical Isolates

scholarly journals Мікрофлора урогенітального тракту жінок із неспецифічними вульвовагінітами та вагінозами у Дніпропетровській області

2012 ◽  
Vol 3 (1) ◽  
pp. 111-117
Author(s):  
A. O. Ponedilok ◽  
V. G. Gavryliuk ◽  
Y. V. Khlopova ◽  
A. I. Vinnikov
Keyword(s):  
Escherichia Coli ◽  
Candida Albicans ◽  
Proteus Mirabilis ◽  
Age Groups ◽  
Clinical Isolates ◽  
E Coli ◽  
Fluoroquinolone Antibiotics ◽  
Causative Agents ◽  
Etiological Agents

The spectrum of causative agents of nonspecific infections of the women urogenital tracts is studied. It is established that the typical etiological agents of the vaginosis are yeast-like fungi Candida albicans (35.7 %) and Escherichia coli (30.2 %), and the clinical isolates of E. coli (47.3 %) and Proteus mirabilis (15.8 %) are usual for vulvovaginitis. The frequency of detection of the causative agents of inflammatory genito-urinary diseases in women of different age groups varies: strains of E. coli are often found in patients of 1–12 years (47.3 %) and in women of 43–66 years old (36.0 %), but C. albicans – in patients of 18–42 years (39.0 %). High levels of the resistance to penicilline, tetracycline and fluoroquinolone antibiotics in selected clinical isolates of opportunistic microorganisms are determined. 

Prevalence of AmpC β-lactamase in Clinical Isolates of Escherichia coli, Klebsiella spp., and Proteus mirabilis in a Tertiary Hospital in Tehran, Iran

2016 ◽  
Vol 9 (12) ◽  
Author(s):  
Hiva Saffar ◽  
Neda Asgari Niaraki ◽  
Arash Ghahroudi Tali ◽  
Zohre Baseri ◽  
Alireza Abdollahi ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Proteus Mirabilis ◽  
Tertiary Hospital ◽  
Clinical Isolates ◽  
Klebsiella Spp

Procaryotic Expression of Single-Chain Variable-Fragment (scFv) Antibodies: Secretion in L-Form Cells of Proteus mirabilis Leads to Active Product and Overcomes the Limitations of Periplasmic Expression in Escherichia coli

1998 ◽  
Vol 64 (12) ◽  
pp. 4862-4869 ◽  
Author(s):  
Jörg F. Rippmann ◽  
Michaela Klein ◽  
Christian Hoischen ◽  
Bodo Brocks ◽  
Wolfgang J. Rettig ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Proteus Mirabilis ◽  
Binding Activity ◽  
Host Cells ◽  
Heterologous Proteins ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
E Coli ◽  
Active Product ◽  
Periplasmic Expression

ABSTRACT Recently it has been demonstrated that L-form cells ofProteus mirabilis (L VI), which lack a periplasmic compartment, can be efficiently used in the production and secretion of heterologous proteins. In search of novel expression systems for recombinant antibodies, we compared levels of single-chain variable-fragment (scFv) production in Escherichia coliJM109 and P. mirabilis L VI, which express four distinct scFvs of potential clinical interest that show differences in levels of expression and in their tendencies to form aggregates upon periplasmic expression. Production of all analyzed scFvs in E. coli was limited by the severe toxic effect of the heterologous product as indicated by inhibition of culture growth and the formation of insoluble aggregates in the periplasmic space, limiting the yield of active product. In contrast, the L-form cells exhibited nearly unlimited growth under the tested production conditions for all scFvs examined. Moreover, expression experiments with P. mirabilis L VI led to scFv concentrations in the range of 40 to 200 mg per liter of culture medium (corresponding to volume yields 33- to 160-fold higher than those with E. coli JM109), depending on the expressed antibody. In a translocation inhibition experiment the secretion of the scFv constructs was shown to be an active transport coupled to the signal cleavage. We suppose that this direct release of the newly synthesized product into a large volume of the growth medium favors folding into the native active structure. The limited aggregation of scFv observed in the P. mirabilis L VI supernatant (occurring in a first-order-kinetics manner) was found to be due to intrinsic features of the scFv and not related to the expression process of the host cells. The P. mirabilis L VI supernatant was found to be advantageous for scFv purification. A two-step chromatography procedure led to homogeneous scFv with high antigen binding activity as revealed from binding experiments with eukaryotic cells.

scholarly journals Mechanistic insights into synergy between nalidixic acid and tetracycline against clinical isolates of Acinetobacter baumannii and Escherichia coli

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Amit Gaurav ◽  
Varsha Gupta ◽  
Sandeep K. Shrivastava ◽  
Ranjana Pathania
Keyword(s):  
Escherichia Coli ◽  
Acinetobacter Baumannii ◽  
Nalidixic Acid ◽  
Bacterial Infections ◽  
Clinical Isolates ◽  
Hospital Environment ◽  
Infection Model ◽  
Drug Resistant ◽  
E Coli

AbstractThe increasing prevalence of antimicrobial resistance has become a global health problem. Acinetobacter baumannii is an important nosocomial pathogen due to its capacity to persist in the hospital environment. It has a high mortality rate and few treatment options. Antibiotic combinations can help to fight multi-drug resistant (MDR) bacterial infections, but they are rarely used in the clinics and mostly unexplored. The interaction between bacteriostatic and bactericidal antibiotics are mostly reported as antagonism based on the results obtained in the susceptible model laboratory strain Escherichia coli. However, in the present study, we report a synergistic interaction between nalidixic acid and tetracycline against clinical multi-drug resistant A. baumannii and E. coli. Here we provide mechanistic insight into this dichotomy. The synergistic combination was studied by checkerboard assay and time-kill curve analysis. We also elucidate the mechanism behind this synergy using several techniques such as fluorescence spectroscopy, flow cytometry, fluorescence microscopy, morphometric analysis, and real-time polymerase chain reaction. Nalidixic acid and tetracycline combination displayed synergy against most of the MDR clinical isolates of A. baumannii and E. coli but not against susceptible isolates. Finally, we demonstrate that this combination is also effective in vivo in an A. baumannii/Caenorhabditis elegans infection model (p < 0.001)

Sign in / Sign up

Export Citation Format

Share Document